Apoptosis and its clinical significance for bladder cancer therapy

BJU International

Volumn 83, Issue 1, 1999, Pages 1-10

  Kelly, J D ^a,c   Williamson, K E ^a   Irvine, A E ^b   Hamilton, P W ^b   Weir, H P ^b   Anderson, N H ^b   Keane, P F ^a   Johnston, S R ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c Institute of Clinical Sciences B   (United Kingdom)

Author keywords

Apoptosis; BCG; Bcl 2; Cell death; p53; TNF; Tumour suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYTOTOXIC AGENT; DNA FRAGMENT; FAS LIGAND; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR;

APOPTOSIS; BLADDER CANCER; FLOW CYTOMETRY; HUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; DNA FRAGMENTATION; DNA, NEOPLASM; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENES, BCL-2; GENES, P53; HUMANS; MEMBRANE GLYCOPROTEINS; URINARY BLADDER NEOPLASMS;

EID: 0033033428     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00871.x     Document Type: Review

References (115)

1. 1 Kerr JFR, Winterford CM, Harmon BV. Apoptosis, its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26
2. 2 Evans DL, Tilby M, Dive C. Differential sensitivity to the induction of apoptosis by cisplatinum in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res 1994; 54: 1596-603
3. 5 Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death. Br J Cancer 1991; 64: 192-6
4. 4 Lowe SW. Clinical implications of p53-dependent apoptosis. Cancer Res 1997; 57: 411-4
5. 5 Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997; 27: 1-20
6. 6 Schwartz LM, Smith SW, Jones ME, Osbourne LA. Do all programmed cell deaths occur via apoptosis. Proc Natl Acad Sci USA 1993; 90: 980-4
7. 7 Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-54
8. 8 Malyapa RS, Sawada S. Cell-cycle dependence of heat-induced interphase death in mouse L5178Y cells. Radiation Res 1991; 125: 134-40
9. 9 Majno G, Joris I. Apoptosis, oncosis and necrosis. An overview of cell death. J Pathol 1995; 146: 3-16
10. 10 Arends MJ, Morris RG, Wyllie AH. Apoptosis: the role of the endonuclease. Am J Pathol 1990; 136: 593-608
11. 11 Fesus L, Davies PJ, Piacentini M. Molecular mechanisms in the program of cell death by apoptosis. Eur J Cell Biol 1991; 56: 170-7
12. 12 Fleming W. Uber die Bildung von Richtunsfifuren in Saugethiereiern beim Unter-gang Graafcher Follikel. Arch Anat Entw Gesh 1885; 221-4
13. 13 Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57
14. 14 Stewart RJG, Lawson AH, Weaver JPA. The ultrastructure of transitional cell carcinomas of the human urinary bladder treated with ethoglucid or mitomycin. J Urol 1988; 139: 1355-8
15. 15 Kerr JFR, Gobe GC, Winterford CM et al. Anatomical methods in cell death. In Wilson EL, Matsudaura P, eds, Methods in Cell Biology. 1st edn. San Diego: Academic Press Inc 1995: 1-26
16. 16 Harrison DJ. Counting apoptosis - why and how? J Clin Pathol: Mol Pathol 1996; 49: M245-6
17. 17 Potten CS. What is an apoptotic index measuring? A commentary. Br J Cancer 1996; 74: 1743-8
18. 18 Kelly JD, McManus D, Williamson KE, Hamilton PW, Keane PF, Johnston SR. Validation of a rapid method to quantify apoptosis in superficial bladder cancer. Br J Urol 1997; 80: 927-32
19. 19 Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994; 173: 333-9
20. 20 Chyle V, Pollack A, Czerniak B et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiation Oncol 1996; 35: 281-7
21. 21 Kerr JFR, Harmon BV, Tomei LD, Cope FO, eds, Definition and incidence of apoptosis: an historical perspective. In Apoptosis: The molecular basis of cell death. Cold Spring Harbour Laboratory Press 1991: 5-23
22. 22 Weedon D, Searle J, Kerr JFR. Apoptosis; its nature and implications for dermatopathology. Am J Dermatopath 1979; 1: 133-44
23. 23 Wyllie AH, Kerr JFR, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980; 68: 251-305
24. 24 Peitsch MC, Polzar B, Stephan H, Crompton T, MacDonald HR, Tschopp J. Characterisation of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death). EMBO J 1993; 12: 371-7
25. 25 Knight CR, Rees RC, Griffin M. Apoptosis: a potential role for the cytosolic transglutaminase and its importance in tumour progression. Biochem Biophys Acta 1991; 1096: 312-8
26. 26 Goodlad RA, Levi S, Lee CY, Mandir N, Hodgson H, Wright NA. Morphometry and cell proliferation in endoscopic biopsies: evaluation of a technique. Gastroenterology 1991; 101: 1235-41
27. 27 Hamilton PW, Allen DC, eds. Quantitative clinical pathology. 1st edn. Oxford: Blackwell Science, 1995: 23
28. 28 Compton MM. A biochemical hallmark of apoptosis: Internucleosomal degradation of the genome. Cancer Metastasis Rev 1992; 11: 105-13
29. 29 Frankfurt OS, Byrnes JJ. Seckinger D, Sugarbaker EV. Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. Oncol Res 1993; 5: 37-43
30. 30 Panchalingham S, Reynolds GM, Lammas DA, Rowlands DC, Kumararatne DS. Simple method for pretreatment of tissue sections for the detection of apoptosis by in situ end-labelling and in situ nick translation. J Clin Pathol: Mol Pathol 1996; 49: M273-77
31. 31 King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996; 155: 316-20
32. 32 McKenna SL, Hoy T, Holmes JA, Whittaker JA. Jackson H, Padua RA. Flow cytometric apoptosis assays indicate different types of endonuclease activity in haematopoietic cells and suggest a cautionary approach to their quantitative use. Cytometry 1998; 31: 130-6
33. 33 Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993; 170: 1-8
34. 34 Eastman A, Barry MA. The origins of DNA breaks - a consequence of DNA damage, DNA repair, or apoptosis? Cancer Invest 1992; 10: 229-40
35. 35 Collins RJ, Harmon BV, Gobe GC, Kerr JFR. Internucleosomal DNA cleavage should not be the sole criterion for identifying apoptosis. Int J Radiat Biol 1992; 61: 451-3
36. 36 Wijsman J, Jonker RR, Keijzer Rea. A new method to detect apoptosis in paraffin sections: in situ end-labelling of fragmented DNA. J Histochem Cytochem 1993; 41: 7-12
37. 37 Merritt AJ, Jones LS, Pollen CS, Cotter TG, Martin SJ, eds, Apoptosis in murinec intestinal crypts. In Techniques in Apoptosis. 1st edn. London: Portland Press Ltd, 1996: 269-300
38. 38 Griffiths TRL, Mellon JK, Pyle GA, Shenton BK, Neal DE. p53 and ploidy assessed by flow cytometry in bladder washings. Br J Urol 1995; 76: 575-9
39. 39 van Engeland M, Raemaekers FCS, Schutte B, Reutelingsperger CPM. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996; 24: 131-9
40. 40 Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CPM. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Meth 1995; 184: 39-51
41. 41 Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817-29
42. 42 Vaux DL, Haeker G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994; 76: 777-9
43. 43 Hedgecock EM, Sulston JE, Thompson NJ. Mutations affecting programmed cell deaths in the nematode Caenorhabditis elegans. Science 1983; 220: 1277-9
44. 44 Hengartner MD, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homologue of the mammalian protooncogene bcl-2. Cell 1994; 76: 665-76
45. 45 Yuan Y, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 1993; 75: 641-52
46. 46 Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62
47. 47 Kroemer G, Petit PX, Zamzami N, Vayssier JL, Mignotte B. The biochemistry of apoptosis. FASEB 1995; 19: 1277-87
48. 48 Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-6
49. 49 Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumour cells. Genes Dev 1996; 10: 2438-51
50. 50 Cox LS. Review article: multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21. J Pathol 1997; 183: 134-40
51. 51 El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-25
52. 52 Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21-Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cycline dependent kinases. Cell 1993; 75: 805-16
53. 53 El-Deiry WS, Harper JW, O'Connor PM et al. AF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis. Cancer Res 1 994; 54: 1169-74
54. 54 Miyashita T, Krajewska M, Gang Wang H et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805
55. 55 Polyak K, Xia Y, Zweiwer JL, Kinzler JL, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-5
56. 56 Wyllie A. Clues in the p53 murder mystery. Nature 1997; 389: 237-8
57. 57 Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78: 539-42
58. 58 Chresta CM, Masters JRW, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res 1996; 56: 1834-41
59. 59 Kawasaki T, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/Waf-1/Cip-1 and/or p53 gene alterations. Int J Cancer 1996; 68: 501-5
60. 60 Harney JV, Murphy DM, Jones M, Mothersill C. Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients. Br J Cancer 1995; 71: 25-9
61. 61 Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumour progression in bladder cancer. New Eng J Med 1994; 331: 1259-65
62. 62 Esrig D, Spruck CHI, Nicholas PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-97
63. 63 Oyasu R, Nan L, Szumel RC, Kawamata H, Hirohashi S. p53 gene mutations in human urothelial carcinomas: analysis hy immunohistochemistry and single-strand conformation polymorphism. Modern Pathol 1995; 8: 170-6
64. 64 Sarkis AS, Bajorin DF, Reuter VE et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384-90
65. 65 Kurth ICK, Schultz M, Stout P, Fan K. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus calmette-guerin treatment. Urology 1997; 49: 541-7
66. 66 Lacombe L, Dalbagni G, Zhang ZFC-CC, Fair WR, Herr HW, Reuter VE. Overexpression of p53 protein in a high risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: correlation to clinical outcome. J Clin Oncol 1996; 14: 2646-52
67. 67 Cote RJ. Esrig D, Groshen S, Jones PA, Skinner DG. p53 and the treatment of bladder cancer. Nature 1997; 385: 123-4
68. 68 Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713-6
69. 69 Lowe SW, Jacks T. Letter. Nature 1997; 385: 124-5
70. 70 Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited! J Pathol 1994; 172: 1-4
71. 71 Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56
72. 72 Boldin MP, Goncharov TM, Golstev YV, Wallace D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in FAS/APO1 and TNF receptor induced cell death. Cell 1996; 85: 803-15
73. 73 Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S. Fas and perform pathways as major mechanisms of T-cell mediated cytotoxicity. Science 1994; 265: 528-30
74. 74 Itoh N, Tsujimoto H, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 1993; 151: 621-7
75. 75 Vaux DL, Aguila HL, Weissman IL. Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. Int Immunol 1992; 4: 821-4
76. 76 Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65
77. 77 Staal FJT, Anderson MT, Staal GEJ. Herzenberg LA, Gitler C. Redox regulation of signal transduction: tyrosine phosphorylation and calcium flux. Proc Natl Acad Sci USA 1994; 91: 3619-22
78. 78 Chiba T, Takahashi S, Sato N, Ishii S, Kikuchi K. Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells. Eur J Immunol 1996; 26: 1164-9
79. 79 Mizutani Y, Okada Y, Yoshida O, Fukumoto M, Bonavida B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer 1997; 79: 1180-9
80. 80 Thomas DJ, Birch PJ, Vickers J et al. Glutathione-S-transferase expression in transitional cell carcinoma of the bladder. Br J Urol 1993; 72: 740-3
81. 81 Ahn H, Lee E, Kim K, Lee C. Effect of glutathione and its related enzymes on chemosensitivity of renal cell carcinoma and bladder carcinoma cell lines. J Urol 1994; 151: 263-7
82. 82 Patard JJ. Chopin DK, Boccon-Gibod L, mechanisms of action of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. World J Urol 1993; 11: 165-8
83. 83 Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain of BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147: 1636-42
84. 84 Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 1992; 52: 4286-90
85. 85 Shemtov MM, Li-Wei Cheng D, Kong L et al. Lak cell mediated apoptosis of human bladder cells involves a pH-dependent endonuclease system in the cancer cell: possible mechanism of BCG Therapy. J Urol 1995; 154: 269-74
86. 86 Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on regulation of the mitochondrial permeability pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerget Biomembr 1994; 26: 509-17
87. 87 Zoratti M, Szabo I. Electrophysiology of the inner mitochondrial membrane. J Bioenerget Biomembr 1996; 26: 543-53
88. 88 Petit PX, Susin SA, Zamzami N, Mignotte B, Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett 1996; 396: 7-13
89. 89 Strasser A, Harris AW, Jacks T. DNA damage can induce apoptosis in proliferating lymphoid cells via p53 indepen-dent mechanisms inhibitable by Bcl-2. Cell 1994; 79: 329-39
90. 90 Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a leukemic cell line. Blood 1993; 81: 154-7
91. 91 Walton WI, Whysong D, O'Connor PM, Hockenbury D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates mitogen mustard and camphotericin induced apoptosis. Cancer Res 1993; 53: 1853-61
92. 92 Fisher TC, Milner AE, Gregory CD et al. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993; 53: 3321-6
93. 93 Reed JC. Bcl-2 and regulation of programmed cell death. J Cell Biol 1994; 124: 1-6
94. 94 Korsmeyer SJ. Regulators of cell death. Trends Genet 1995; 11: 101-5
95. 95 Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189-92
96. 96 Oltvai ZN, Milliman CL, Korsmeyer SJ. Bel-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19
97. 97 Zha H, Aime-Sempe C, Sato T, Reed JC. Proapoptotic protein Bax heterodimerises with Bcl-2 and homodimerises with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Bio Chem 1996; 21: 7440-4
98. 98 Apakama I, Robinson MC, Walter NM et al. Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996; 74: 1258-62
99. 99 Krajewski S, Blomquist C, Franssila K et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and short survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-8
100. 100 Ferrieres G, Cuny M, Simony-Lafontaine J. Jacquemier J. Rouleau C, Guilleux F. Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas. J Pathol 1997; 183: 204-11
101. 101 Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Cell Biol 1991; 88: 6961-5
102. 102 Gazzaniga P, Gallucci M, Gradilone A et al. Detection of bcl-2 RNA in low-grade tumours of the urinary bladder. Eur J Cancer 1995; 131A: 2119-20
103. 103 Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J Pathol 1996; 49: 395-9
104. 104 Glick SH, Howell LP, Devere White RW. Relationship of p53 and bcl-2 to prognosis in muscle invasive transitional cell carcinoma of the bladder. J Urol 1996; 155: 1754-7
105. 105 Alnemri ES, Livingston DJ. Nicholson DW et al. Human ICE/Ced-3 protease nomeculture. Cell 1996; 87: 171-5
106. 106 Dulic V, Kaufmann WK, Wilson SJ et al. Dependent inhibition of cyclin-dependent kinase activates in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013-23
107. 107 Chinnaiyan AM, Dixit VM. The cell death machine. Curr Biol 1996; 6: 556-62
108. 108 Clem RJ, Cheng EH, Karp CL et al. Modulation of cell death by Bcl-xl through caspase interaction. Proc Natl Acad Sci USA 1998; 95: 554-9
109. 109 Cheng EH, Kirsch DG, Clem RJ et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997; 278: 1966-70
110. 110 Cotter FE, Johnson P, Hall P. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-55
111. 111 Webb A, Cunningham D, Cotter F et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-41
112. 112 Trauth BC, Klas C, Peters AMJ et al. Monoclonal antibody-mediated tumour regression by induction of apoptosis. Science 1989; 245: 301-5
113. 113 Bischoff JR, Kim DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science 1996; 274-373
114. 114 van der Meijden AP, Hall RR, Kurth KH, Bouffioux C, Sylvester R. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept. Br J Urol 1996; 77: 634-7
115. 115 Popert RJ. Goodall J, Coptcoat MJ, Thompson PM, Parmar MK, Masters JR. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Br J Urol 1994; 74: 195-9